CTSA and Parkinson disease: Finally, LRRK2 kinase inhibition fully normalized BMP and GSL levels in lysosomes, restored lysosomal proteolysis in cellular models, and showed trends toward reduction of GSL levels in CSF from human subjects, highlighting the potential of LRRK2 kinase inhibition as a therapeutic approach to correct lysosomal dysfunction in PD.